Last reviewed · How we verify
400 IU Vitamin D3
At a glance
| Generic name | 400 IU Vitamin D3 |
|---|---|
| Also known as | Materna |
| Sponsor | King Fahad Medical City |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of Cofrogliptin on Beta-Cell Function in LADA Patients (NA)
- Resveratrol for the Prevention of Bone Loss in Postmenopausal Women (NA)
- Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19 (NA)
- Preventive Effect of a Dietary Supplement With Two Probiotic Limosilactobacillus Reuteri Strains on Excessive Crying and Colic in Healthy Newborns. (NA)
- Effect of Vitamin D as Adjuvant Therapy in Preterm Infants With Neonatal Sepsis (PHASE4)
- Vitamin D Deficiency in Adults Following a Major Burn Injury (PHASE4)
- Can Vitamin D Supplementation in the First Year of Life Prevent Food Allergy in Infants? The VITALITY Trial: Parts 1&2 (PHASE4)
- Can Vitamin D Reduce the Burden of COVID-19? (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 400 IU Vitamin D3 CI brief — competitive landscape report
- 400 IU Vitamin D3 updates RSS · CI watch RSS
- King Fahad Medical City portfolio CI